Listed

Pulse Biosciences, Inc.: Form 10-Q for the period ended Mar 31, 2026

Filed with the SEC on May 14, 2026 and accepted by EDGAR at May 14, 2026, 13:02 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2026-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2026-01-01 to 2026-03-31$401.0kus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue3 months2026-01-01 to 2026-03-31$370.0kus-gaap:CostOfRevenue
Research and development3 months2026-01-01 to 2026-03-31$12.6mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2026-01-01 to 2026-03-31$6.6mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2026-01-01 to 2026-03-31−$19.1mus-gaap:OperatingIncomeLoss
Net income3 months2026-01-01 to 2026-03-31−$18.6mus-gaap:NetIncomeLoss
Basic EPS3 months2026-01-01 to 2026-03-31−$0.27us-gaap:EarningsPerShareBasic
Operating cash flow3 months2026-01-01 to 2026-03-31−$14.6mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure3 months2026-01-01 to 2026-03-31$33.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2026-03-31$68.3mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2026-03-31$71.1mus-gaap:AssetsCurrent
Total assetsAt period end2026-03-31$81.6mus-gaap:Assets
Current liabilitiesAt period end2026-03-31$9.8mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2026-03-31$15.3mus-gaap:Liabilities
Shareholders' equityAt period end2026-03-31$66.3mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001437749-26-016897. Last ingested by Listed: Oct 24, 2026, 15:14 ET. Listed shows no prices and gives no investment advice.